Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma

Tamaki Ueda1, Yuhki Koga1, Hiroshi Yoshikawa2, Mika Tanabe2, Kanako Yamana2, Utako Oba1, Kentaro Nakashima1, Hiroaki Ono1, Takuya Ichimura3, Shunj Hasegawa3, Wakako Kato1, Tetsuko Kobayashi1,4, Hideki Nakayama1,4, Yasunari Sakai1, Tadamas Yoshitake2, Saiji Ohga5, Yoshinao Oda6, Shigenobu Suzuki7, Koh-Hei Sonoda2 and Shouichi Ohga1

Abstract

Background: Retinoblastoma is an ocular tumor in infants with cancer predisposition. Treatment of the rare tumor needs to be optimized for ocular preserved survival without second primary malignancy (SPM).

Methods: We studied the outcomes of all patients with retinoblastoma at a tertiary center in 1984–2016, when preservation method changed from radiotherapy (1984–2001) to systemic chemotherapy (2002–2016).

Results: One-hundred sixteen infants developed unilateral- (n = 77), bilateral- (n = 38), or trilateral-onset (n = 1) tumor. Ten (8.6%) had a positive family history, despite a few studies on RB1 gene. Contralateral disease occurred in one unilateral-onset case. One-hundred eight of 155 eyes (70%) were enucleated. Nine binocular survivors were from 5 bilateral- and 4 unilateral-onset cases. Two survivors received bilateral enucleation. Six deaths occurred; brain involvement (including 3 trilateral diseases) in 4 bilateral-onset, systemic invasion in a unilateral-onset, and SPM (osteosarcoma) in a bilateral-onset case(s). Two others survived SPM of osteosarcoma or lymphoma. The 10-year overall survival (OS: 98.5% vs. 91.3%, p = 0.068) and binocular survivors (13.2% vs. 5.2%, p = 0.154) between bilateral- and unilateral-onsets did not differ statistically. The 10-year OS and cancer (retinoblastoma/SPM)-free survival (CFS) rates of all patients were 94.9 and 88.5%, respectively. The proportion of preserved eyes did not differ between radiotherapy and chemotherapy eras. The CFS rate of bilateral-onset cases in systemic chemotherapy era was higher than that in radiotherapy era (p = 0.042). The CFS rates of bilateral-onset patients with neoadjuvant chemotherapy (upfront systemic therapy for preservation) was higher than those without it (p = 0.030).

Conclusions: Systemic chemotherapy and local therapy raised OS and binocular survival rates of bilateral-onset patients similarly to those of unilateral-onset patients. All but one death was associated with a probable germline defect of the RB1 gene. Neoadjuvant stratified chemotherapy may support the long-term binocular life with minimized risk of SPM.

Keywords: RB1 gene, Radiotherapy, Chemotherapy, Laser-therapy, Cancer predisposition, Blindness
Background
Retinoblastoma, which is the most common intraocular tumor of childhood, arises from a mutation in RB1 [1]. It usually affects young infants; the worldwide incidence of one case per 15,000–20,000 live births [2]. Non-surgical control became the mainstay for ocular preservation after 1980, in order to reduce the risk of late complications and second primary malignancy (SPM) after external beam radiotherapy [3]. In the 1990s, neoadjuvant systemic chemotherapy then emerged as an initial therapy for complete survival and better visual outcome [4]. Intra-ophthalmic artery chemotherapy (IAC) has been also introduced for effective globe salvage and reducing the risk of SPM [5–8].

The first goal in the treatment of retinoblastoma is to prevent extraocular invasion and metastasis of the primary tumor. In developing countries, this tumor is still diagnosed at an advanced stage [9]. The majority of patients having metastatic retinoblastoma die within approximately 6 months [10]. The annual incidence of retinoblastoma in Japan is estimated to be ≤100 per year, and the treatment regimen has yet been unified [11]. Even in developed countries, very young infants are hard to complete both IAC and neoadjuvant systemic chemotherapy (upfront intravenous chemotherapy) in a single institution [6, 12]. There is little information on the late effects of systemic chemotherapy on mortality and morbidity along with the risk of developing SPM in association with a germline mutation of RB1.

To search for better practices for retinoblastoma, we retrospectively studied the final outcomes of patients in our tertiary institution over three decades, focusing on the survival and ocular preservation of survivors. The best treatment goal was discussed with respect to cancer-free and blindness-free survival of patients with retinoblastoma.

Methods
Data collection
One-hundred thirty-one patients who received a diagnosis of retinoblastoma were consecutively registered in Kyushu University Hospital from 1984 to 2017 (Fig. 1). The inclusion criteria were patients who received a diagnosis and treatment in Kyushu University, and who underwent IAC in the National Cancer Center Hospital (to standardize the treatment modality). Patients with underlying diseases were excluded from the study. Twelve patients who were only referred to our hospital for follow-up after treatment elsewhere, and 3 patients for whom no information was available were excluded. A total of 116 patients with 155 affected eyes were enrolled in the study. The following data were collected from the medical records and questionnaires distributed to attending doctors and/or families: age at the diagnosis, sex, laterality, treatment (radiotherapy, systemic chemotherapy, and/or local therapy), SPM, family history. The primary endpoint in the study is overall survival (OS), and the secondary ones were cancer (retinoblastoma/SPM)-free survival (CFS) and ocular outcome (number of preserved eyeballs). This study was certified by the Institutional Review Board of Kyushu University (#29–244).
Diagnosis and classification
The diagnosis of retinoblastoma was clinically and histopathologically made by ophthalmologists and pathologists. The stage of extraocular disease was classified according to the International Retinoblastoma Staging System (IRSS) [13]. Intraocular disease was classified by Reese and Ellsworth (R-E) system or the Intraocular Classification of Retinoblastoma (ICRB) [14]. Staging to determine the treatment choice in each patient was independently assessed by two expert ophthalmologists in different institutions.

Treatment modality
Intravenous chemotherapy was applied for cases with IRSS stage II-IV extraocular disease, or progressive intraocular disease without vitreous seeding. For local therapy, laser irradiation or cryotherapy or direct vitreous injection of melphalan were performed in Kyushu University Hospital. IAC and brachytherapy were performed by the National Cancer Center Japan. Brachytherapy was included as local therapy because of the report on the negligible effect on the development of SPM [15].

External beam radiotherapy was performed for the preservation of one eye in bilateral cases or for the control of extraocular disease until 2002 (Fig. 2). Intravenous cancer chemotherapy was used for the control of extraocular lesions until 2000, using cyclophosphamide (CPM), vincristine (VCR), pirarubicin (THP-ADR), and cisplatin (CDDP). The combination chemotherapy of VCR, etoposide, and carboplatin (VEC therapy) as local therapy was introduced as adjuvant and neoadjuvant therapy in 1998 and 2002, respectively. The standard dosages of 3 drugs were used; VCR (1.5 mg/m², day 1), etoposide (150 mg/m², day 1, 2), carboplatin (560 mg/m², day 1). The administered dose was weight-converted to 1 m² = 30 kg for patients weighing < 10 kg. The dose was reduced by 50–75% of reduced for newborn infants or patients with a poor condition. The number of cycles of VEC was individualized according to the aforementioned classifications, pathological consequences, appearance of the fundus, extension, and chemoresponse of the tumor.

The first-line therapy for patients with unilateral disease was enucleation prior to 1987, local therapy for ocular preservation since 1988, and neoadjuvant therapy from 2002, according to the stage. The first-line therapy for bilateral cases was enucleation of the advanced stage eye and preservation of the eye on the other side prior to 1997, and neoadjuvant therapy with local therapy from 1998. Multidrug chemotherapy was administered as first-line therapy for central nervous system (CNS) involvement or distant metastasis throughout the study period.

Statistical analyses
The chi-squared test or Fisher’s exact test was used to compare categorical variables. The Mann-Whitney U test was used to compare the mean values of continuous variables. The OS and CFS rates with 95% confidence intervals (CI) were estimated by the Kaplan–Meier method, and assessed by a log-rank test. OS was defined as the period from the date of the diagnosis of retinoblastoma until death of any cause or the final observation. CFS was defined as the period from the date of the diagnosis of retinoblastoma until the date of the “progression” of retinoblastoma, the diagnosis of SPM, for
death from any cause or the final observation. The term “progression” was defined as growth, regrowth, vitreous dissemination in the affected eyeball, or extraocular invasion or metastasis of the primary tumor. Transient minimal growth was excluded from “progression”. Contralateral ocular development and CNS involvement during the study period were considered “progression”, because most patients did not undergo a mutation study of the germline RB1 gene and CNS diseases were diagnosed by imaging but not all histopathological studies. The observation period was calculated from the diagnosis to the last contact (the date at visit or questionnaire response) with patients and/or their families directly. All results were updated to September 30, 2017. A logistic regression model was used to investigate factors associated with death or the occurrence of SPM. P-values of < 0.05 were considered to indicate statistical significance. Statistical analyses were performed with Excel statistical software and JMP software (ver.13 SAS institute, Cary, NC, U.S.A) programs.

Results

Demographics and the first-line treatment

They consisted of 77 unilateral- (66%), 38 bilateral- (33%), and one trilateral-onset patients (Table 1). Bilateral-onset patients had a higher rate of family history of retinoblastoma, a younger age at diagnosis and a longer observation period than the unilateral-onset ones. Figure 2 shows the historical changes in the patient number and the initial non-surgical treatment modality. The annual incidence was average 4 cases per year. The ratio of bilateral- to unilateral-onset patients in radiotherapy era (1984–2001) was higher than that in preservation chemotherapy era (2002–2016) (44% vs. 22%, p = 0.029). The mortality rates decreased from 9.1% in the former to 1.6% in this century. The trilateral-onset was only one death after 2000. The proportion of preserved eyes did not increase from the former to this century (33 to 26%). Contralateral disease occurred only in one unilateral-onset patient. (Additional file 1: Figure S1A).

Treatment course and outcomes

The treatments, deaths and ocular preservation in survivors are shown in Table 2. During the observation (median 133 months; range, 10–403), 6 deaths occurred from CNS (including 3 trilateral) disease in 4 bilateral-onset, metastasis in a unilateral-onset, and SPM (osteosarcoma) in a bilateral-onset case(s). Two survivors became blind for both enucleations. The binocular survivor’s rate of bilateral-onset (13.2%) was high compare with unilateral-onset ones (5.2%, p = 0.154). Ten (6 bilateral- and 4 unilateral-onset) received IAC and systemic chemotherapy (Table 2, Additional file 1: Figure S1A, and Figure S1B). Detailed treatments of unilateral (A) and bilateral-onset patients (B) are shown in Additional file 1: Figure S1. Final outcomes are represented by death (black box, n = 5), binocular (double bold frame, n = 2) or monocular enucleation (single bold frame, n = 103). According to the reported risk of SPM [16], patients with systemic chemotherapy (n = 33) and/or external beam radiotherapy (n = 25) may have an increased risk of cancer predisposition (gray box). All survivors achieved complete remission (CR) at the time of last observation.

In 77 unilateral-onset cases (Additional file 1: Figure S1A), 69 underwent enucleation and 8 received preservation therapy. After enucleation, the presence of residual tumor cells was microscopically suspected in 17 cases. One developed a contralateral lesion 5 months later; the other died of dissemination 27 months after diagnosis (Pt-4, Table 3). Fifty of 69 enucleated patients attained a CR without additional

| Table 1 Demographics and initial treatment in 116 patients at diagnosis of retinoblastoma |
|---------------------------------------------------------------|
| All patients Unilateral Bilateral Trilateral p-value |
| Number of patients 116 77 38 1  |
| eyes 155 77 76 2  |
| Male / female 58 / 58 36 / 41 21 / 17 1 / 0 0.432 |
| Positive family history b) 10 2 8 0 0.002 |
| Age at diagnosis c), month 13 (0–101) 20 (0–101) 5 (0–28) 18 3.17 × 10–7 |
| Observation period b), month 133 (10–403) 113 (10–403) 188 (15–370) 18 0.026 |
| Initial treatment |
| Enucleation alone 69 69 0 0 |
| Local therapy alone 6 0 6 0 |
| External beam radiotherapy 19 2 17 0 |
| Systemic chemotherapy 22 6 15 1 |

a) Statistical comparisons between patients with unilateral tumors and those with bilateral tumors were performed, using chi-square test, Fisher’s exact test and Mann-Whitney U test
b) The germline mutation of RB1 was studied in only a few patients
c) Each value represents the median age or observation period (months), with the range in parenthesis
therapy, one of whom developed T-cell lymphoma 82 months after the diagnosis of retinoblastoma (Pt-8, Table 4). Among 17 cases with microscopic invasion suspected in the enucleated site, 15 obtained a CR after external beam radiotherapy and/or systemic chemotherapy and 2 attained a CR after no additional therapy. Among 8 cases with local therapy, 6 received neoadjuvant chemotherapy and two resulted in enucleation. Two others underwent enucleation after external beam radiotherapy.

In 38 bilateral-onset cases (Additional file 1: Figure S1B), 27 first underwent one enucleation, and 11 received local therapy for binocular preservation. Among 27 patients died. Among 11 cases with preservation therapy, only one died and all survivors escaped blindness. Among 8 cases with local therapy, 6 received neoadjuvant chemotherapy and two resulted in enucleation. Two others underwent enucleation after external beam radiotherapy.

In 38 bilateral-onset cases (Additional file 1: Figure S1B), 27 first underwent one enucleation, and 11 received local therapy for binocular preservation. Among 27 patients died. Among 11 cases with preservation therapy, only one died and all survivors escaped blindness. Among 8 cases with local therapy, 6 received neoadjuvant chemotherapy and two resulted in enucleation. Two others underwent enucleation after external beam radiotherapy.

Two survivors were blind due to binocular loss.

Deceased cases and second malignancy
Six deceased and 3 SPM cases are summarized in Table 3 and Table 4, respectively. Two bilateral-onset cases had trilateral disease 5 and 23 months after the first diagnosis, respectively (Pts-1, 3). All 3 cases with trilateral lesions died within 2 years (Pts-1~3). Osteosarcoma developed in 2 bilateral-onset cases (Pts-6 and 7). T-cell lymphoma did in a unilateral-onset case without no radiotherapy or systemic chemotherapy. Five advanced cases with CNS or

### Table 2 All treatments, deaths, and ocular preservations in survivors

| Disease                  | Patients | Treatments                          | Number of Patients | Death | Binocular Survivors (%) |
|--------------------------|----------|-------------------------------------|--------------------|-------|-------------------------|
| Trilateral-onset n = 1   | n = 1    | RT and Systemic chemotherapy         | 1                  | 1 (Pt 2) | 0 (0%)                 |
| Bilateral-onset n = 38   | n = 38   | Enucleation and/or Local therapy alone | 5                  | 0     | 1 / 5 (25%)             |
|                          |          | Enucleation and/or Local therapy with RT | 8                  | 2 (Pt 3, Pt 6) | 2 / 6 (33%) |
|                          |          | Systemic chemotherapy                | 25                 | 0 / 8* | 0 (0%)                  |
|                          |          | with RT (and IAC)                    | 10 (1)             | 2     | 15 (13%)                |
|                          |          | w/o RT (and IAC)                     | 15 (5)             | 0     | 0 (0%)                  |
|                          |          |                                      |                    | 4/38 (10.5%) | 5/38 (13.2%) |
| Unilateral-onset n = 77  | n = 77   | Enucleation and/or Local therapy alone | 52                 | 0     | 0 / 52 (0%)             |
|                          |          | Enucleation and/or Local therapy with RT | 2                  | 0     | 0 / 2 (0%)              |
|                          |          | Systemic chemotherapy                | 23                 | 0 / 4 | 0 (0%)                  |
|                          |          | with RT                              | 5                  | 1     | 4 / 18 (22%)            |
|                          |          | w/o RT (and IAC)                     | 18 (4)             | 0     | 0 / 52 (0%)             |
|                          |          |                                      |                    | 1/77 (1.3%) | 4/77 (5.2%) |

*Two survivors were blind due to binocular loss

Deceased cases and second malignancy
Six deceased and 3 SPM cases are summarized in Table 3 and Table 4, respectively. Two bilateral-onset cases had trilateral disease 5 and 23 months after the first diagnosis, respectively (Pts-1, 3). All 3 cases with trilateral lesions died within 2 years (Pts-1~3). Osteosarcoma developed in 2 bilateral-onset cases (Pts-6 and 7). T-cell lymphoma did in a unilateral-onset case without no radiotherapy or systemic chemotherapy. Five advanced cases with CNS or

### Table 3 Characteristics, treatment and secondary neoplasms of deceased patients

| Pt | Sex | Age at diagnosis, death | Observation period | Onset | Invasion | Treatment for retinoblastoma | Family history | Secondary malignancy | Causes of death | Onset |
|----|-----|-------------------------|--------------------|-------|----------|-----------------------------|----------------|---------------------|-----------------|-------|
| 1  | male | 21 m, 37 m             | 15 m               | bilateral | CNS (tri.) | yes[^a] noLt NR no trilateral disease | 1987 |
| 2  | male | 17 m, 37 m             | 18 m               | trilateral | CNS (tri.) | yes[^b] yes no no no trilateral disease | 2014 |
| 3  | male | 0 m, 24 m              | 23 m               | bilateral | CNS (tri.) | yes[^b] no Lt NR no trilateral disease | 1989 |
| 4  | male | 21 m, 49 m             | 27 m               | unilateral | systemic | yes[^b] noLt no no no systemic disease | 1985 |
| 5  | female | 93 m                | 92 m               | bilateral | CNS (meta) | yes[^b] no Pr → Rt yes no CNS metastasis | 1990 |
| 6  | male | 7 m, 298 m             | 290 m              | bilateral | CR → 2nd | yes[^b] noLt no Os secondary Os | 1991 |

[^a]: Invasion means the sites affected during the advanced disease course
[^b]: External beam radiotherapy for metastasis

m months; meta metastasis; tri trilateral; Lt left; Pr preservation; NR not recorded; RB retinoblastoma; CR complete remission; Os osteosarcoma; RT external beam radiotherapy
bone marrow involvement died within 100 months after the diagnosis (Additional file 1: Figure S2).

**Survival, risk of developing cancer, and ocular outcomes**

The 10-year OS rates (median ± SE%) and CFS rates of all patients were 94.9 ± 2.3% and 88.5 ± 3.2%, respectively (Fig. 3a). The 10-year CFS rates of all and bilateral-onset cases, but not unilateral-onset cases in 2002–2016 were higher than those in 1984–2001 (98.4 ± 1.6% vs. 80.0 ± 5.5%, \( p = 0.003 \), 100 ± 0% vs. 70.0 ± 9.3%, \( p = 0.042 \), respectively) (Fig. 4a, c). On the other hand, the 10-year OS rates of all, unilateral-onset, and bilateral-onset cases did not differ between the era of radiotherapy (1984–2001) and chemotherapy (2002–2016) (Figs. 3a, 4b, 3d). The 10-year CFS rates of bilateral-onset cases was lower than seen in unilateral ones (94.0 ± 3.1% vs. 80.7 ± 6.6%, \( p = 0.035 \)) (Fig. 4d), although the difference of the 10-year OS rates did not reach the statistical significance (98.5 ± 1.5% vs. 91.3 ± 4.9%, \( p = 0.068 \)) (Fig. 4b).

The 10-year CFS, but not OS, rates of cases with neoadjuvant chemotherapy were higher than those without it (100% vs. 69.6%, \( p = 0.003 \)) (Fig. 5a, b), while the final proportion of binocular survivors did not differ between two groups (13.3% vs. 13.0%, \( p > 0.999 \)). The Cox-hazards model indicated that neoadjuvant chemotherapy (OR 44.4, 95%CI 3.65–540, \( p = 0.003 \)) and a positive family history (OR 13.1, 95%CI 1.06–162, \( p = 0.045 \)) were independent variables that discriminated patients who attained radiotherapy-free, disease-free and SPM-free survival after binocular salvage (Table 5).

**Discussion**

This is the first and largest cohort of retinoblastoma patients treated with systemic chemotherapy in Japan. The CFS rates of binocular-onset patients improved in systemic chemotherapy era. Upfront systemic chemotherapy with local therapy has sustained the high OS and CFS rates but limitedly ocular preservation. Despite the

**Table 4** Characteristics of patients with secondary neoplasm

| Pt | Sex | Age at diagnosis | Duration months | Disease course and treatment | second malignancy | Family history | Outcome, observation period |
|----|-----|------------------|----------------|-----------------------------|-------------------|----------------|-----------------------------|
| 6  | male | 7 m              | 19             | bilateral→Enuc. + R,L → CR  | Os→C + S + R → PD | no              | died of Os, 290 m           |
| 7  | male | 22 m             | 7 y            | bilateral→prEnuc. + R,L → CR| Os→C + S → CR    | no              | alive on CR, 235 m          |
| 8  | male | 19 m             | 8 y            | unilateral→Enuc. → CR       | Lym → C → CR     | no              | alive on CR, 167 m          |

Enuc enucleation; prEnuc ocular preservation but subsequent enucleation; CR complete remission; L local therapy; C systemic chemotherapy; S surgical intervention; R external beam radiotherapy; Os osteosarcoma; Lym T-cell lymphoma

**Fig. 3** The cumulative probability of survival rates of patients after the diagnosis. Each value was assessed by a log-rank test. Kaplan-Meier curves showing a the 10-year overall survival (OS) versus cancer (retinoblastoma/second primary malignancy [SPM])-free survival (CFS) rates of all patients, b the 10-year CFS rates of all patients in 1984–2001 versus 2002–2016, c the 10-year CFS rates of bilateral-onset patients in 1984–2001 versus 2002–2016, d the 10-year CFS rates of unilateral-onset versus bilateral-onset patients
high CFS rates over 85%, 5 of 6 deaths were associated with a probable germline defect of RB1 gene because of their trilateral diseases and SPM. These results stressed the need of stratified protocol of upfront chemotherapy according to cancer-predisposing grade of patients.

In the United States, 75% of children with retinoblastoma have advanced or refractory disease that cannot be cured with focal treatments alone, and thus require external beam radiotherapy, systemic chemotherapy, or enucleation [17]. In developing countries [18], systemic chemotherapy may have a greater utility in practice for not only preservation but also saving lives because of the delayed diagnosis and lower availability of focal treatments, including IAC. In Japan, systemic preservation chemotherapy has been conducted by pediatric oncologists in collaboration with ophthalmologists. In the present study, the proportion of unilateral cases in the non-preservation era (enucleation and radiotherapy, 1984–2001) was lower than seen in the preservation era (systemic chemotherapy, 2002–2016). This may be explained by the early diagnosis and intervention in Japan of this century. It also represents the centralization of advanced cases or preservable cases to our hospital after 2000, when it was officially designated as the largest center for pediatric cancer treatment in western Japan. The present cohort was completed with long-term collaboration between pediatricians and ophthalmologists in the Tokyo (IAC) and Kyushu (systemic chemotherapy) centers, with the primary endpoint of saving life, with globe salvage and the preservation of vision in the affected eyes. Although it previously allowed most eyes to be salvaged from enucleation, IAC alone does not replace systemic chemotherapy for the control of refractory disease [5]. This is the first report demonstrating the effects of upfront systemic chemotherapy on cancer-free survival, it also reports—albeit insufficiently—the binocular outcomes of Japanese survivors with retinoblastoma.

The major concern is the effect of systemic chemotherapy on the tumor growth and secondary tumorigenesis. Extraocular metastasis occurs even if careful local therapy is given to the refractory case individually. Adjunctive systemic chemotherapy prevents the development of extraocular metastasis [19]. In the present study, no cases receiving neoadjuvant chemotherapy (with an exception of trilateral disease) died of progressive disease or SPM; however, the refractory case enucleation was inevitable for bilateral-onset cases. In cases of neoadjuvant chemotherapy, no trilateral disease occurred during the observation period. Chemoreduction could prevent or delay the onset of trilateral retinoblastoma, although the prophylactic effects have not been verified [20].

During our long observation, 3 of 116 patients (2.6%) suffered from SPM over 5 years after the diagnosis. In a Japanese cohort of 754 patients treated from 1964 to 2007 [21], 21 patients (2.8%) developed SPM. Thereafter, the cumulative incidence rate of SPM increased to 4.3%
at 20 years and 19.1% at 40 years. On the other hand, a pediatric oncology study group in Japan [22] reported that the cumulative incidence of SPM at 20 years was highest in patients with osteosarcoma (13.1%), followed by those with hepatoblastoma (8.4%) and retinoblastoma (6.6%). In this setting, the current neoadjuvant therapy needs to be optimized in terms of the balance between the intensity for preservation and the much longer-term cancer risk over 20 years.

Treatments for metastatic or trilateral disease are problematic for survival [23]. The other issue is the intensity of neoadjuvant chemotherapy for newborns and very young infants. In our cohort, 16 patients received the diagnosis within 3 months after birth. We conducted reduced-dose VEC chemotherapy for them. To reduce the late effects, single-agent systemic chemotherapy may be recommended for young infant as “bridge therapy” to provide time for the infant to grow to a size that permits successful arterial cannulation, at which time IAC can be performed [24]. On the other hand, standard chemotherapy protocols occasionally failed to treat the neonatal retinoblastoma because of the lack of a significant vascular supply in smaller tumor foci [25].

![Kaplan-Meier curves showing](image)

**Table 5** Multivariable analysis for the association variables discriminating non-irradiated survivors with disease-free both eyes

| Variables                        | Odds ratio | 95% confidence interval lower-upper limit | P-value |
|----------------------------------|------------|------------------------------------------|---------|
| Neoadjuvant chemotherapy         | 44.4       | 3.65–540                                 | 0.0029  |
| Positive family history          | 13.1       | 1.06–162                                 | 0.045   |
| Unilateral RB at diagnosis       | 7.32       | 0.68–84.2                                | 0.11    |
| male                             | 2.63       | 0.35–19.9                                | 0.35    |

Survivors in whom both eyes were disease-free (n = 7) vs. others (n = 83) who received enucleation or external beam radiotherapy (n = 26)

*Either parents or sibling(s) received a diagnosis of retinoblastoma
Recently, molecular targeted drugs and gene therapy have been reported as the promising therapeutic option for advanced cases and/or young infants with retinoblastoma [26–28]. Rare deaths in our institution might account for the probable germline defect of RB1 gene, although most patients received no genetic study. To pursue a better quality of life, in addition to a stratified neoadjuvant chemotherapy protocol, neonatal screening is being more actively promoted for high-risk families in Japan under collaboration between ophthalmologists and pediatricians [29].

The present study has some limitations. First, the analysis based on international classification was not possible due to insufficient information regarding tumor stage. Second, the genetic study was not done in most cases because of personal information and health insurance system in Japan. Third, the follow-up time might be insufficient to determine the risk of SPM in patients with retinoblastoma.

Conclusion
The survival and ocular outcomes of bilateral cases improved in the era of systemic chemotherapy for preservation. The neoadjuvant chemotherapy may support their long-term outcomes with less impact on the risk of developing SPM.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12887-020-1923-7.

Additional file 1: Figure S1. (Online Resource) The treatment courses and outcomes of unilateral-onset retinoblastoma (A) and bilateral-onset retinoblastoma (B). White box indicates observation and/or local therapy. Gray box indicates the “second primary malignancy risk-inducible therapy” of external beam radiotherapy or systemic chemotherapy. Black box indicates death. Single and double bold frames indicate monocular and binocular enucleation, respectively. Star symbol indicates second primary malignancy (SPM). CR: complete remission. Chemo Tx: systemic chemotherapy, BM: bone marrow, RT: external beam radiotherapy, PD: progressive disease, IAC: intra-ophthalmic artery chemotherapy. Each patient number corresponds to the deceased case in Figure S2.

Figure S2. (Online Resource) The detailed treatment course from diagnosis to death of all deceased patients. RT(m): external beam radiotherapy for metastasis, RT(e): external beam radiotherapy for eye, RT(s): external beam radiotherapy for SPM. Chemotherapy: cyclophosphamide, VCR: vincristine, MTX: Methotrexate, ETH: etoposide, Carboplatin, P: cisplatin. Gray box indicates the second primary malignancy risk-inducible therapy of external beam radiotherapy or systemic chemotherapy. Black box indicates death. Single and double bold frames indicate monocular and binocular enucleation, respectively. Star symbol indicates second primary malignancy (SPM). CR: complete remission, Chemo Tx: systemic chemotherapy, BM: bone marrow, RT: external beam radiotherapy, PD: progressive disease, IAC: intra-ophthalmic artery chemotherapy. Each patient number corresponds to the deceased case in Figure S2.

Abbreviations
CDDP: Cisplatin; CFS: Cancer-free survival; CNS: Central nervous system; CPM: Cyclophosphamide; IAC: Intra-arterial chemotherapy; OS: Overall survival; RT: External beam radiotherapy; SPM: Second primary malignancy; THP-ADR: Pirarubicin; VCR: Vinсristine; VEC: Vinсristine-etoposide-carboplatin.

Acknowledgements
We thank Prof. Emeritus Tatsuro Ishibashi (Department of Ophthalmology, Kyushu University Hospital), Prof. Hiroshi Honda (Department of Clinical Radiology, Kyushu University Hospital), Prof. Eizhi Ishii, Prof. Akinobu Matsuzaki, Dr. Takeshi Inamitsu and Dr. Aiko Suminoe (Department of Pediatrics, Kyushu University Hospital), along with all staff members who treated the patients in Kyushu University Hospital. We also thank Dr. Brian Quinn (Japan Medical Communication, Fukuoka, Japan) for editing the manuscript.

Authors’ contributions
YK, TU and SO were the principal investigators and take primary responsibility for the paper. UO, KN, HO, TI, WK, TK, and HN performed the clinical management with helpful discussion regarding the completion of the work. HY, MT, KY, SS, and K-HS completed the ophthalmologic treatment and collected data. YO made the pathological diagnosis. SH and YS performed long-term observation and supported the completion of the study. All authors approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work.

Funding
Shionogi Scholarship donation support (Grant Number: RS2017A001030879) funded editorial assistance and improvements to the English language of the paper. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
Complete raw data is available on request. Kindly contact the corresponding authors for raw data.

Ethics approval and consent to participate
This study was certified by the Institutional Review Board of Kyushu University (#29–244). This study is a retrospective study, and most of the subjects are those who have completed follow-ups in pediatrics and ophthalmology, and those who visit about once a year even during follow-up. It is not possible to conduct individual explanations on research using explanatory documents and obtain consent and conduct research. Therefore, an explanatory document regarding this research will be sent at the same time as the questionnaire, and the consent of the research participation will be given by returning the questionnaire. In addition, information on this study will be made public on the homepage for those who cannot move the questionnaire due to moving away. Based on the above requirements, this study has obtained the informed consent of patients.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 2. Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 3. Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan. 4. Division of Pediatrics, Kyushu Cancer Center, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 5. Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 6. Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 7. Department of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Received: 22 October 2019 Accepted: 10 January 2020
Published online: 28 January 2020

References
1. Kamihara J, Bourdeaut F, Foukle WD, Molenar JJ, Mossé YP, Nakagawa A, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017;23:98–106.
2. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129–31.
3. Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med. 2014;65:171–84.

4. Fabian ID, Onadim Z, Karais C, Duncan C, Chowdhury T, Scheinberg I, et al. The management of retinoblastoma. Oncogene. 2018;37:151–60.

5. Yousef YA, Soliman SE, Astudillo PPP, Durairaj P, Dinarat H, Chan HSL, et al. Intravenous arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol. 2016;134(5):538–91. https://doi.org/10.1001/jamaophthalmol.2016.0244.

6. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.

7. Shields CL, Mangandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:453–60.

8. Abramson DH, Shields CL, Jabbour P, Teixeira LF, Fonseca JRF, Marques MCP, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retin Vitreovit. 2017;3(40). https://doi.org/10.1186/s40942-017-0093-8.

9. Selistre SGA, Maestri MK, Santos-Silva P, Schüler-Faccini L, Guimarães LSP, Giacomazzi J, et al. Retinoblastoma in a pediatric oncology reference center in southern Brazil. BMC Pediatr. 2016;16:48. https://doi.org/10.1186/s12887-016-0579-9.

10. Hu H, Zhang W, Wang Y, Huang D, Huang D, Shi J, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18(107). https://doi.org/10.1186/s12886-018-0772-8.

11. The committee for the national registry of retinoblastoma. The national registry of retinoblastoma in Japan (1983–2014). Jpn J Ophthalmol. 2018;62:409–23.

12. Okimoto S, Nomura K. Clinical manifestations and treatment of retinoblastoma in Kobe children's hospital for 16 years. J Pediatr Ophthalmol Strabismus. 2014;51:222–9.

13. Chantada G, Doz F, Antonelli CB, Grundy R, Clare Stannard FF, Dunkel IJ, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801–5.

14. Novetsky DE, Abramson DH, Kim JW, Dunkel U. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies—an analysis of impact. Ophthalmol Genet. 2009;30:40–4.

15. Temming P, Wieland R, Jöckel K, Eisele L, Le Guin CH, Schündeln MM, et al. Incidence of secondary cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: a report from the German reference center. Pediatr Blood Cancer. 2017;64:71–80.

16. Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, Kleinerman RA. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32:3284–90.

17. Abramson DH, Fabius AW, Francis JH, Marr BP, Dunkel U, Brodie SE, et al. Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. Ophthalmic Genet. 2017;38:16–21.

18. Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries. Semin Ophthalmol. 2016;31:310–6.

19. Honavar SG. Emerging options in the management of advanced intraocular retinoblastoma. Br J Ophthalmol. 2009;93:848–9.

20. Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119:269–72.

21. Araki Y, Matsuyama Y, Kobayashi Y, Toyokawa S, Inoue K, Suzuki S, Makimoto A. Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 745 patients in Japan. Jpn J Clin Oncol. 2011;41:373–9.

22. Ishida Y, Maeda M, Adachi S, Inada H, Kawaguchi H, Hori H, et al. Secondary cancer after a childhood cancer diagnosis: viewpoints considering primary cancer. Int J Clin Oncol. 2018;23:1178–88.

23. Caselli D, Tamburini A, La Torre A, Polazzi L, Tintori V, Bambi F, et al. High-dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: report of five cases. Pediatr Transplant. 2014;18:631–6.

24. Gobin YP, Dunkel U, Marr BP, Francis JH, Brodie SE, Abramson DH. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322. https://doi.org/10.1371/journal.pone.0044322.

25. Kívelä TT, Haidjistilouan N. Neonatal retinoblastoma. Asia Pac J Oncol Nurs. 2017;4:197–204.

26. Zhang J, Benvenute CA, Mcevoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329–34.

27. Goldsmith ZK, Coppess W, Irvine AS, Yuan K, Barsh SR, Ritter MK, et al. Targeting the platelet-derived growth factor-beta stimulatory circuitry to control retinoblastoma seeds. Invest Ophthalmol Vis Sci. 2018;59:4948–95.

28. Li U, Chen WEI, Wang Y, Tang L, Han M. Long non-coding RNA H19 regulates viability and metastasis, and is upregulated in retinoblastoma. Oncol Lett. 2018;15:842–32.

29. Skølet AH, Gombos DS, Gallie BL, Kim JW, Shields CL, Marr BP, et al. Screening children at risk for retinoblastoma consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018;125:453–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions